Research Article
Formulation and Evaluation of Guggul Lipid Nanovesicles for Transdermal Delivery of Aceclofenac
Table 3
Physicochemical characterization of selected nanovesicle formulations (PC-1 and GL-1) after stability studies.
| Parameters | Formulation code | 0th Day |
30th Day |
90th Day |
180th Day | 4°C | 25°C | 4°C | 25°C | 4°C | 25°C |
| Size (nm) | PC-1 | 147 ± 2.5 | 163 ± 1.3 | 212 ± 4.2 | 285 ± 2.4 | 346 ± 2.8 | 412 ± 3.7 | 698 ± 4.7 | GL-1 | 121 ± 1.1 | 122 ± 1.5 | 125 ± 1.7 | 129 ± 2.8 | 143 ± 2.5 | 138 ± 1.6 | 189 ± 1.9 |
| PDI | PC-1 | 0.297 ± 0.001 | 0.351 ± 0.003 | 0.472 ± 0.007 | 0.449 ± 0.002 | 0.548 ± 0.003 | 0.562 ± 0.009 | 0.723 ± 0.007 | GL-1 | 0.153 ± 0.004 | 0.167 ± 0.002 | 0.171 ± 0.001 | 0.179 ± 0.001 | 0.185 ± 0.007 | 0.182 ± 0.005 | 0.198 ± 0.001 |
| potential (mV) | PC-1 | −42 ± 1.2 | −43 ± 1.8 | −44 ± 1.3 | −46 ± 3.1 | −48 ± 3.5 | −48 ± 2.9 | −51 ± 2.6 | GL-1 | −25 ± 1.1 | −26 ± 1.7 | −27 ± 2.9 | −26 ± 2.9 | −28 ± 1.6 | −27 ± 1.9 | −29 ± 2.4 |
| Entrapment efficiency (%) | PC-1 | 47.6 ± 1.8 | 46.8 ± 1.3 | 34.8 ± 2.1 | 38.2 ± 1.5 | 28.1 ± 2.6 | 32.6 ± 2.1 | 17.2 ± 2.2 | GL-1 | 78.9 ± 1.1 | 78.4 ± 1.3 | 77.3 ± 1.5 | 77.6 ± 1.5 | 73.2 ± 1.4 | 74.1 ± 1.8 | 70.4 ± 1.7 |
| In vitro % Cumulative drug release | PC-1 | 73.91 ± 1.4 (in 24 hrs) | 79.2 ± 1.9 (in 18 hrs) | 91.4 ± 2.2 (in 18 hrs) | 85.5 ± 2.8 (in 20 hrs) | 94.3 ± 2.3 (in 14 hrs) | 93.7 ± 1.4 (in 12 hrs) | 95.3 ± 1.9 (in 8 hrs) | GL-1 | 70.06 ± 1.3 (in 24 hrs) | 72.4 ± 1.9 (in 24 hrs) | 75.6 ± 1.5 (in 24 hrs) | 78.8 ± 2.2 (in 24 hrs) | 81.3 ± 1.9 (in 24 hrs) | 89.5 ± 1.6 (in 24 hrs) | 95.2 ± 1.4 (in 24 hrs) |
|
|
All data expressed as mean ± S.D.; ; .
|